In one of the cell lines and in 4 of 19 (21%) NKCL primary tumor samples, constitutive JAK3 activation was related to an acquired mutation (A573V or V722I) in the JAK3 pseudokinase domain.

(NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel investigational drug that acts as a covalent inhibitor of two key immune signaling kinases, ITK and JAK3. Details about ...